Delcath Systems Reports 70% Revenue Growth in Q3 2026 and Raises Full-Year Guidance to $115 Million–$117 Million
Delcath Systems (DCTH) reported Q3 2026 revenue of $35.1M, up 70% YoY, driven by higher sales of its liver cancer treatment products. The company raised its full-year revenue guidance to $115M–$117M. Net income increased to $7.0M, and gross margin improved to 89%. HEPZATO KIT revenue grew 69% to $32.7M, while European CHEMOSAT revenue rose to $2.4M. Adjusted EBITDA increased to $11.5M, and operating cash flow reached $8.2M. Delcath also advanced its clinical development programs.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise signal accelerating commercial adoption of HEPZATO KIT, likely driving short‑term price appreciation.
Market read
Strong quarterly performance and raised guidance make DCTH a potential short‑term buy.
What to watch
Potential regulatory delays for upcoming IND filing could temper growth expectations.
Background
Delcath Systems (NASDAQ:DCTH) is a biotech firm focused on hepatic perfusion therapies for liver cancers.
Ticker impact
Delcath Systems reported Q3 2026 revenue up 70% YoY and raised full-year revenue guidance to $115M-$117M.
likely upward pressure as market prices in higher revenue outlook
The company posted strong quarterly results and increased guidance, a clear catalyst for buying interest.
Market effects
Boosts outlook for liver‑cancer treatment sector and related biotech peers.
Positive for US biotech market; limited broader regional effect.
Modest, confined to specialty oncology space.
Counterpoint
If guidance is overly optimistic, future earnings may miss expectations, prompting a pullback.
Key entities
- companyDelcath Systems
Biotech company reporting earnings and guidance.
